Other clinical trials have reported that the use of statins (rosuvastatin), proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9), and some anti-inflammatory drugs (colchicine) have the potential to stop the progression or even regress atherosclerosis. The gene discussed is PCSK9; the disease is atherosclerosis.